Operating loss: ($3.8M) (-72.7%); cash & equiv: $11.2M (-23.2%).
The company will conduct a 28-day bridging toxicology study on its lead anti-infective product candidate, SYN-004 next month followed by an IND application. A Phase 1a/1b trial should begin in 2H 2014 with preliminary top-line results by year end. A Phase 2 trial will follow in 1H 2015.
A Phase 1 trial for its anti-pertussis product candidate, SYN-005, should begin in Q1 2015 with top-line data available after 90 days. A Phase 2 trial will follow with top-line results expected by 2H 2015. The company intends to request Orphan Drug Designation for SYN-005 for the treatment of pertussis (whooping cough).
Expect an additional capital raise in the near future.